OncoMatch/Clinical Trials/NCT07348042
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
Is NCT07348042 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including RGL-270 and Adebelimab for tumor, solid.
Treatment: RGL-270 · Adebelimab — This study is a phase I clinical trial of multi-center, open label, dose increase and dose expansion. It aims to evaluate the safety, tolerance, PK characteristics, immunogenicity and initial efficacy of personalized new antigen mRNA vaccine RGL-270 (hereinafter referred to as RGL-270) alone and combined with adebelizumab in patients with high risk of recurrence of malignant solid tumors after radical treatment.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radical resection
malignant solid tumors confirmed by histology or cytology after radical resection
Cannot have received: immune cell or tumor vaccine treatment (tumor infiltration lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), T cell receptor chimeric T cells (TCR-T), therapeutic tumor vaccines)
Have received immune cell or tumor vaccine treatment, including but not limited to tumor infiltration lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), T cell receptor chimeric T cells (TCR-T) and therapeutic tumor vaccines
Lab requirements
Blood counts
neutrophil count (ANC) ≥1.5×10^9/L, lymphocyte count (LYM) ≥0.5×10^9/L, platelet count (PLT) ≥1× normal lower limit (LLN), hemoglobin (Hb) ≥90g/L
Liver function
total bilirubin (TBIL) ≤1.5× normal upper limit (ULN), ALT and AST ≤2.5×ULN, serum albumin (ALB) ≥30g/L, serum creatine (Scr) ≤1×ULN
Cardiac function
Left ventricular blood ejection fraction (LVEF) ≥50%; QTcF <470 ms (Fridericia correction)
The functions of important organs meet the following criteria... (see full text for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify